Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Sialic acid binding immunoglobulin-like lectin 19, pseudogene (SIGLEC19P; ENSG00000267895) is a non-functional member of the Siglec family. Siglecs are I-type lectins, usually functioning as cell-surface immune receptors that bind sialic acids and modulate cell signaling or immune responses[1][2][3][4]. However, SIGLEC19P is classified as a pseudogene, meaning it does not produce a functional protein in humans and thus lacks the cellular functions or disease associations typical of active Siglec receptors. There are no known interacting drugs, mechanisms of action, or clinical relevance associated with this locus. If you require structured data for a functional Siglec, please provide the exact name or ENSG (for example, "Siglec-7" or "SIGLEC7").
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sialic acid binding immunoglobulin-like lectin 19, pseudogene (SIGLEC19P).